ES2985999T3 - Conjugados de proteínas - Google Patents

Conjugados de proteínas Download PDF

Info

Publication number
ES2985999T3
ES2985999T3 ES16775707T ES16775707T ES2985999T3 ES 2985999 T3 ES2985999 T3 ES 2985999T3 ES 16775707 T ES16775707 T ES 16775707T ES 16775707 T ES16775707 T ES 16775707T ES 2985999 T3 ES2985999 T3 ES 2985999T3
Authority
ES
Spain
Prior art keywords
protein
linker
conjugate
mmol
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16775707T
Other languages
English (en)
Spanish (es)
Inventor
Emiliano Clo
Mikael Kofod-Hansen
Henrik Sune Ramirez-Andersen
Nils Langeland Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2985999(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2985999T3 publication Critical patent/ES2985999T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16775707T 2015-10-01 2016-09-30 Conjugados de proteínas Active ES2985999T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15187937 2015-10-01
PCT/EP2016/073470 WO2017055582A1 (en) 2015-10-01 2016-09-30 Protein conjugates

Publications (1)

Publication Number Publication Date
ES2985999T3 true ES2985999T3 (es) 2024-11-08

Family

ID=54252136

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16775707T Active ES2985999T3 (es) 2015-10-01 2016-09-30 Conjugados de proteínas

Country Status (7)

Country Link
US (1) US11292825B2 (enExample)
EP (1) EP3355931B1 (enExample)
JP (1) JP6949832B2 (enExample)
CN (1) CN108136043B (enExample)
ES (1) ES2985999T3 (enExample)
MA (1) MA43348A (enExample)
WO (1) WO2017055582A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CA3071852A1 (en) * 2017-08-04 2019-02-07 Amgen Inc. Method of conjugation of cys-mabs
US20240050583A1 (en) * 2020-12-08 2024-02-15 Harbour Biomed (Shanghai) Co., Ltd Protein-drug conjugate and site-specific conjugating method
CN113024669B (zh) * 2021-03-12 2022-06-14 北京华科泰生物技术股份有限公司 含氨基或羧基基团物质标记的rbp抗体、人rbp免疫层析检测试剂盒及其制备方法
CN115819611B (zh) * 2021-12-30 2024-05-28 君合盟生物制药(杭州)有限公司 生长激素融合蛋白及其制备方法和用途
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途
WO2025184552A2 (en) * 2024-03-01 2025-09-04 The Scripps Research Institute Dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286509C (enExample)
DE257197C (enExample)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
CA2658039A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
CA2379388C (en) 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
PE20020908A1 (es) 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
MXPA04004385A (es) 2001-11-12 2004-11-29 Univ Cardiff Variaciones de hormona de crecimiento en humanos y sus usos.
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
CN101987871A (zh) 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
RU2007132188A (ru) 2005-01-25 2009-03-10 Селл Терапьютикс, Инк. (Us) Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo
WO2006079641A2 (en) 2005-01-27 2006-08-03 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
CA2601745A1 (en) 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
AU2006324488B2 (en) 2005-12-12 2013-03-21 Abcam Limited Production of conjugates
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US8093068B2 (en) 2006-10-26 2012-01-10 Centocor, Inc. Methods for use in human-adapting monoclonal antibodies
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
AU2008257923B2 (en) 2007-05-30 2013-03-21 Genexine, Inc. Immunoglobulin fusion proteins
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US8586532B2 (en) 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
CN102625813A (zh) 2008-06-20 2012-08-01 诺华公司 具有降低的聚集的免疫球蛋白
WO2010001196A1 (en) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
AR072596A1 (es) * 2008-07-23 2010-09-08 Hanmi Pharmaceutical Co Ltd Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
JP5808671B2 (ja) 2008-11-10 2015-11-10 ノヴォ ノルディスク アー／エス 機能グループｉｉ莢膜遺伝子クラスターを有しないｅ．ｃｏｌｉｂｌ２１株
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN104147611A (zh) 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
AU2010318542B2 (en) 2009-10-29 2015-08-27 Janssen Biotech Inc. Antibody glycosylation variants
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
EP3473261A1 (en) 2010-05-21 2019-04-24 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
EP2694528A1 (en) 2011-04-05 2014-02-12 Martin-Protean, LLC Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EA037979B1 (ru) * 2012-02-27 2021-06-18 Амуникс Оперейтинг Инк. Композиции конъюгата xten и способы их получения
WO2013170272A2 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
CA2928087A1 (en) 2013-11-26 2015-06-04 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
CA2966352A1 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
ES2905085T3 (es) 2014-09-17 2022-04-07 Novo Nordisk As Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161)
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
PL3334462T3 (pl) 2015-08-14 2022-05-09 RemeGen Biosciences, Inc. Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
EP3863680A1 (en) 2018-10-10 2021-08-18 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use

Also Published As

Publication number Publication date
CN108136043B (zh) 2022-09-06
JP6949832B2 (ja) 2021-10-13
EP3355931C0 (en) 2024-06-26
EP3355931B1 (en) 2024-06-26
WO2017055582A1 (en) 2017-04-06
CN108136043A (zh) 2018-06-08
US11292825B2 (en) 2022-04-05
US20180282387A1 (en) 2018-10-04
JP2018535195A (ja) 2018-11-29
EP3355931A1 (en) 2018-08-08
MA43348A (fr) 2018-08-08

Similar Documents

Publication Publication Date Title
ES2985999T3 (es) Conjugados de proteínas
ES2932285T3 (es) Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo
JP5591243B2 (ja) ペプチド又はタンパク質のアシル化の方法
US11471537B2 (en) Oligomer extended insulin-Fc conjugates
JP6038248B2 (ja) プロリン／アラニンランダムコイルポリペプチドの生合成およびその使用
ES2625735T3 (es) Análogos y derivados de GLP-1
ES2913803T3 (es) Derivados de GLP-1 diacilados
CN107108709B (zh) Fgf21衍生物及其用途
ES2818109T3 (es) Modificaciones de proteínas específicas para un sitio
KR102372857B1 (ko) 폴리에틸렌 글리콜 유도체 및 이의 용도
EA020326B1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
ES2759061T3 (es) Inmunoglobulina híbrida que contiene unión no peptidílica
KR20230104118A (ko) Glp-1 전구약물 및 이의 용도
JP2020520918A (ja) Ｍｉｃ−１化合物およびその使用
US20210393745A1 (en) Oligomer extended insulin-fc conjugates and their medical use
ES3037396T3 (en) Method for preparing long-acting drug conjugate through preparation of novel intermediate
ES2389835T3 (es) Glicoproteínas mutantes
ES2874513T3 (es) Derivados de GLP-1 diacilados
HK1234647A1 (en) Hybrid immunoglobulin containing non-peptidyl linkage
HK1234647B (en) Hybrid immunoglobulin containing non-peptidyl linkage